FEB 17, 2021 8:00 AM PST

Urine Test Bypasses the Need for Prostate Biopsies

WRITTEN BY: Tara Fernandez

Researchers have created a urine test for prostate cancer that could make unnecessary biopsies a thing of the past. The high-performing diagnostic accurately detects prostate cancer, with very few false negatives (patients who actually have cancer but test negative).

The test, called MyProstateScore, was developed at the University of Michigan and validated in a cohort of over 1,500 patients. It works by detecting and quantifying levels of a cancer-specific biomarker—signature chromosomal relocations in which the TMPRSS2 and ERG genes combine, triggering the development of prostate tumors.

At present, screening patients for prostate cancer relies on a routine blood test for detecting prostate-specific antigen, or PSA. However, this test is far from perfect, yielding an 80 percent rate of false positives—the majority of men with high PSA levels don’t have prostate cancer. Consequently, patients who are cancer-negative end up having to undergo painful transrectal biopsies to confirm the results. Alternatively, MRIs can visualize potential cancerous masses, but these are costly and not accessible to all patients.

“Our ultimate goal was to determine whether the MyProstateScore test could be a practical, reliable test that could rule out the need for more costly or invasive testing in men referred for a prostate biopsy,” said urology expert and study lead Jeffrey Tosoian.

Tosoian and colleagues validated MyProstateScore in a clinical setting by testing samples taken from 1,525 patients, 338 of which had been positively diagnosed with aggressive prostate cancer. The team found that MyProstateScore could have prevented 387 of these patients from undergoing biopsies as they either had no cancer or a slow-growing (and not medically significant) tumor. Only ten clinically-significant cancer cases slipped through the cracks, testing negative on MyProstateScore.

"In a large, clinically pertinent biopsy referral population, MyProstateScore ≤10 provided exceptional sensitivity and negative predictive value for ruling out grade group ≥2 cancer," wrote the authors.

“The data show that this straightforward, secondary testing approach could reduce the use of more costly and invasive procedures following a PSA test,” Tosoian concluded. The results were published in the Journal of Urology.

 

 

Sources: Journal of Urology, University of Michigan.

 


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 30, 2020
Cancer
Developing Handheld Pulse Lasers to Destroy Cancer Tissue
NOV 30, 2020
Developing Handheld Pulse Lasers to Destroy Cancer Tissue
Many take modern surgeons and surgical methods for granted. In the grand scheme of things, it wasn’t too long ago ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
FEB 03, 2021
Immunology
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
FEB 03, 2021
Severely Ill COVID-19 Patients may have Longer Immunity Against the Virus
Researchers are still studying how long a person can stay immune against COVID-19 following infection. A new study by a ...
FEB 11, 2021
Clinical & Molecular DX
Smartwatches Keep a Close Eye on Parkinson's Patients
FEB 11, 2021
Smartwatches Keep a Close Eye on Parkinson's Patients
Individuals with Parkinson’s disease experience a slow, progressive worsening of symptoms. What can begin as barel ...
FEB 25, 2021
Clinical & Molecular DX
A Better Way to Triage COVID Patients
FEB 25, 2021
A Better Way to Triage COVID Patients
Australian researchers have developed a COVID-19 triaging tool that serves as a crystal ball for healthcare workers. Onc ...
MAR 10, 2021
Clinical & Molecular DX
What's Your Type? Skin Microbes Linked to Dermatitis Severity.
MAR 10, 2021
What's Your Type? Skin Microbes Linked to Dermatitis Severity.
Microbiologists have discovered that the types of bacteria on a dermatitis patient’s skin affect the severity of t ...
Loading Comments...